CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

Convalescent plasma transfusionWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (2)

Name (Synonyms) Correlation
drug3353 mouthrinse with bêta-cyclodextrin and citrox Wiki 1.00
drug3354 mouthrinse without bêta-cyclodextrin and citrox Wiki 1.00

Correlated MeSH Terms (1)

Name (Synonyms) Correlation
D018352 Coronavirus Infections NIH 0.04

Correlated HPO Terms (0)

Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials

1 Open-label Treatment of Severe Coronavirus Disease 2019 (COVID-19) With Convalescent Plasma Collected From Individuals With Documented Infection and Recovery From COVID-19 (SARS-CoV-2)

We hypothesize that use of convalescent plasma donated from individuals recovered from Coronavirus Disease 2019 (COVID-19) will help expedite recovery of individuals with active, severe COVID-19 infection.

NCT04502472 Covid-19 Biological: Convalescent plasma transfusion
MeSH:Coronavirus Infections

Primary Outcomes

Description: Change is clinical status as captured by 7-point ordinal scale to include Death Hospitalized, requiring mechanical ventilation or ECMO Hospitalized, requiring non-invasive ventilation or high flow oxygen Hospitalized, requiring supplemental oxygen Hospitalized, not requiring supplemental oxygen--requiring ongoing medical care (COVID-19 related or otherwise) Hospitalized, not requiring supplemental oxygen-not requiring ongoing medical care (COVID-19 related or otherwise). Not Hospitalized

Measure: Change is clinical status

Time: Time of plasma infusion (day 0) compared to day 7

Description: Presence of any adverse events related to plasma infusion

Measure: Transfusion related events

Time: Within 6 hours of infusion

Secondary Outcomes

Description: Change in 7-point ordinal scale score from time of plasma infusion (day 0-prior to first infusion) to days 14, 21, and 28

Measure: Change is clinical status

Time: Time of plasma infusion (day 0 prior to first infusion) to days 14, 21, and 28

Description: Assess change in Sequential Organ Failure Assessment (SOFA) score

Measure: SOFA score at days 0, 7, 14, 21, 28

Time: Days 0, 7, 14, 21, 28

Description: Total duration of hospital

Measure: Length of Hospital Stay

Time: Days 7, 14, 21, 28

Description: Time to discontinuation of supplemental oxygen

Measure: Supplemental oxygen

Time: Days 7, 14, 21, 28

Description: Need for mechanical ventilation (for those patients not on the ventilator)

Measure: Mechanical Ventilation

Time: Days 7, 14, 21, 28

Description: Time to liberation from mechanical ventilation (for patients on a ventilator)

Measure: Change in mechanical ventilation status

Time: Days 7, 14, 21, 28

Description: All-cause Mortality

Measure: Mortality

Time: Day 28

Description: Change in standard of care inflammatory markers (ferritin, LDH, CRP, D-dimer)

Measure: Change in inflammatory markers

Time: Day 0 to days 7, 14, 21, 28

No related HPO nodes (Using clinical trials)